BioSig Technologies 2024 Q4 Earnings Sustained Losses Despite Revenue Growth

BioSig Technologies(BSGM) reported its fiscal 2024 Q4 earnings on Aug 15th, 2025. The results showed modest top-line growth but continued losses, with no specific guidance adjustments provided. The company did not meet or beat expectations in terms of profitability, as it continues to post net losses.

Revenue
BioSig Technologies recorded a modest 8.3% year-over-year revenue increase in the fourth quarter of 2024, with total revenue rising to $13,000 from $12,000 in the same period of the previous year. While the growth was positive, the absence of segment-specific revenue breakdowns limits deeper insight into the drivers of this increase.

Earnings/Net Income
The company’s earnings per share worsened slightly, with a loss of $0.07 per share in Q4 2024, a 9.8% wider loss compared to the prior year. However, BioSig Technologies made notable progress in reducing its overall net loss, narrowing it to $-1.10 million in 2024 Q4 from a hefty $-6.13 million in the same quarter of 2023, representing an 82.1% reduction. Despite this improvement, the company has continued to post losses for the past five years in the corresponding fiscal quarter, underscoring ongoing financial challenges.

Price Action
BioSig Technologies' stock has experienced mixed price movements, with a 1.78% decline on the latest trading day but a 32.53% surge over the prior full week. The stock has, however, posted a 5.51% drop month-to-date.

Post Earnings Price Action Review
A historical analysis of the stock’s performance reveals that investors who purchased BioSig shares following a quarterly revenue increase and held them for 30 days have experienced exceptional returns. Over the past three years, this strategy has yielded a 443.51% return, significantly outperforming the benchmark index’s 8.21%. The compounded annual growth rate of 955.86% highlights the potential for strong returns from such a strategy.

CEO Commentary
Dr. Christopher J. Cowan, CEO of BioSig Technologies, emphasized the importance of a proposed public offering, which the company plans to use for purchasing gold bullion, working capital, and general corporate purposes. He stressed the alignment of this move with the company’s dual focus on medical technology and gold tokenization through its subsidiary, Streamex. Dr. Cowan expressed cautious optimism, noting that the company remains committed to its strategic direction while acknowledging the uncertainties posed by market conditions.

Guidance
BioSig Technologies expects to complete the public offering, subject to market conditions. The company did not provide specific quantitative guidance or revenue expectations in its earnings report, maintaining a cautious outlook.

Additional News
In unrelated news, at least 14 villagers and a mobile police officer were killed in two separate attacks in the Bokkos Local Government Area of Plateau State, Nigeria, on July 25, 2025. The attacks occurred around 4:00 PM as villagers returned from Bokkos market to Mangor village. A mobile police officer was also killed earlier that day at a checkpoint along Richa Road. Community leaders and local officials have described the events as tragic and an emergency, calling for urgent action from the federal government to address the ongoing violence and security concerns.